title: Estrogen-progesterone and 8-OH-DPAT attenuate the lordosis-inhibiting effects of the 5-HT1A agonist in the VMN.
abstract: Ovariectomized rats were treated for 2 consecutive weeks with 25 micrograms estradiol benzoate followed 48 h later with 500 micrograms progesterone. Bilateral infusions of 200 ng 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) into the ventromedial nucleus of the hypothalamus (VMN) inhibited female sexual behavior on the first but not the second week of hormone priming. Such attenuation on the second week of priming did not appear to result from an enhanced receptivity of the female rats since there were no differences in the L/M ratios prior to drug infusion; nor was the attenuation a consequence of infusion-induced VMN damage since neither saline nor 8-OH-DPAT preinfusions prevented the later inhibitory effects of 8-OH-DPAT on lordosis behavior. However, preinfusion with 8-OH-DPAT may have reduced the duration of the inhibition. Hormone priming (without any VMN infusion) also partially attenuated the effect of 8-OH-DPAT. Both hormone priming and treatment with 8-OH-DPAT were required to eliminate the effects of the second 8-OH-DPAT treatment. Thus, the present results suggest that gonadal hormones, alone, slightly attenuate the effects of agonist activation of 5-HT1A receptors involved in the inhibition of lordosis behavior; that agonist activation of 5-HT1A receptors also produces a slight attenuation; but that both treatments together have a robust protective action against the inhibitory effect of a 5-HT1A agonist on female lordosis behavior.
authors.affiliation: Department of Biology, Texas Woman's University, Denton 76204.
authors.forename: L
authors.initials: L
authors.lastname: Uphouse
authors.forename: M
authors.initials: M
authors.lastname: Caldarola-Pastuszka
authors.forename: S
authors.initials: S
authors.lastname: Maswood
authors.forename: M
authors.initials: M
authors.lastname: Andrade
authors.forename: N
authors.initials: N
authors.lastname: Moore
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D007267:Injections; D010052:Ovariectomy; D011187:Posture / Q000502:physiology*; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D014697:Ventromedial Hypothalamic Nucleus / Q000502:physiology*
chemical_list: D004967:Estrogens; D017366:Serotonin Receptor Agonists; D011374:Progesterone; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin